MedTrace Logo

Role of Circulating Tumor DNA (ctDNA) From LIquid Biopsy in Early Stage NSCLC Resected Lung Tumor Investigation

NCT03553550 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 38

Last updated 2020-11-19

No results posted yet for this study

Summary

The purpose of this research study is to learn more about changes in cell-free tumor DNA in blood samples, also known as a liquid biopsy, as they relate to treatment and response to treatment.

Conditions

  • Non Small Cell Lung Cancer

Interventions

OTHER

biospecimen collection

Peripheral blood collection Archival tissue collection

Sponsors & Collaborators

  • Addario Lung Cancer Medical Institute

    lead OTHER

Principal Investigators

  • Daniel Morgensztern, MD · Washington University School of Medicine

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-06-01
Primary Completion
2020-11-15
Completion
2020-11-15

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03553550 on ClinicalTrials.gov